Targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor

Journal of Ovarian Research

Volumn 3, Issue 1, 2010, Pages

  Komarova, Svetlana ^a,b,c   Roth, Justin ^a,b,c   Alvarez, Ronald ^d   Curiel, David T ^a,b,c   Pereboeva, Larisa ^a,b,c  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c Kentucky   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LUCIFERASE; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INTERACTION; CELL THERAPY; CELL TYPE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 77953588426     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-3-12     Document Type: Article

References (55)

1. Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles. B Hall J Dembinski AK Sasser M Studeny M Andreeff F Marini, Int J Hematol 2007 86 1 8 16 10.1532/IJH97.06230 17675260
2. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. A Nakamizo F Marini T Amano A Khan M Studeny J Gumin J Chen S Hentschel G Vecil J Dembinski M Andreeff FF Lang, Cancer Res 2005 65 8 3307 18 15833864
3. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. M Studeny FC Marini RE Champlin C Zompetta IJ Fidler M Andreeff, Cancer Res 2002 62 13 3603 8 12097260
4. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. M Studeny FC Marini JL Dembinski C Zompetta M Cabreira-Hansen BN Bekele RE Champlin M Andreeff, J Natl Cancer Inst 2004 96 21 1593 603 15523088
5. Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. SC Hung WP Deng WK Yang RS Liu CC Lee TC Su RJ Lin DM Yang CW Chang WH Chen HJ Wei JG Gelovani, Clin Cancer Res 2005 11 21 7749 56 10.1158/1078-0432. CCR-05-0876 16278396
6. Human adipose tissue-derived mesenchymal stromal cells as vehicles for tumor bystander effect: a model based on bioluminescence imaging. M Vilalta IR Degano J Bago E Aguilar SS Gambhir N Rubio J Blanco, Gene Ther 2009 16 4 547 57 10.1038/gt.2008.176 19092860
7. Biodistribution, long-term survival, and safety of human adipose tissue-derived mesenchymal stem cells transplanted in nude mice by high sensitivity non-invasive bioluminescence imaging. M Vilalta IR Degano J Bago D Gould M Santos M Garcia-Arranz R Ayats C Fuster Y Chernajovsky D Garcia-Olmo N Rubio J Blanco, Stem Cells Dev 2008 17 5 993 1003 10.1089/scd.2007.0201 18537463
8. Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. X Duan H Guan Y Cao ES Kleinerman, Cancer 2009 115 1 13 22 10.1002/cncr.24013 19051291
9. Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. M Kanehira H Xin K Hoshino M Maemondo H Mizuguchi T Hayakawa K Matsumoto T Nakamura T Nukiwa Y Saijo, Cancer Gene Ther 2007 14 11 894 903 10.1038/sj.cgt.7701079 17693990 (Pubitemid 47557220)
10. Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. C Ren S Kumar D Chanda J Chen JD Mountz S Ponnazhagan, Stem Cells 2008 26 9 2332 8 10.1634/stemcells.2008-0084 18617688
11. Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. H Xin M Kanehira H Mizuguchi T Hayakawa T Kikuchi T Nukiwa Y Saijo, Stem Cells 2007 25 7 1618 26 10.1634/stemcells.2006-0461 17412895
12. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. S Komarova Y Kawakami MA Stoff-Khalili DT Curiel L Pereboeva, Mol Cancer Ther 2006 5 3 755 66 10.1158/1535-7163.MCT-05-0334 16546991
13. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. MA Stoff-Khalili AA Rivera JM Mathis NS Banerjee AS Moon A Hess RP Rocconi TM Numnum M Everts LT Chow JT Douglas GP Siegal ZB Zhu HG Bender P Dall A Stoff L Pereboeva DT Curiel, Breast Cancer Res Treat 2007 105 2 157 67 10.1007/s10549-006-9449-8 17221158
14. Combination treatment of human umbilical cord matrix stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic human breast cancer in SCID mouse lungs. RS Rachakatla MM Pyle R Ayuzawa SM Edwards FC Marini ML Weiss M Tamura D Troyer, Cancer Invest 2008 26 7 662 70 10.1080/07357900701871134 18608205
15. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. KS Aboody A Brown NG Rainov KA Bower S Liu W Yang JE Small U Herrlinger V Ourednik PM Black XO Breakefield EY Snyder, Proc Natl Acad Sci USA 2000 97 23 12846 51 10.1073/pnas.97.23.12846 11070094
16. Stem and progenitor cell-mediated tumor selective gene therapy. KS Aboody J Najbauer MK Danks, Gene Ther 2008 15 10 739 52 10.1038/gt.2008.41 18369324
17. Magnetic resonance imaging and confocal microscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis. AS Arbab SD Pandit SA Anderson GT Yocum M Bur V Frenkel HM Khuu EJ Read JA Frank, Stem Cells 2006 24 3 671 8 10.1634/stemcells.2005-0017 16179427
18. Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: From biology to therapy. B Dome J Timar A Ladanyi S Paku F Renyi-Vamos W Klepetko G Lang P Dome K Bogos J Tovari, Crit Rev Oncol Hematol 2009 69 2 108 24 10.1016/j.critrevonc.2008.06. 009 18768327
19. T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30(+) cutaneous lymphoma cells. A Hombach JM Muche M Gerken S Gellrich C Heuser C Pohl W Sterry H Abken, Gene Ther 2001 8 11 891 5 10.1038/sj.gt.3301467 11423937
20. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. LJ Cooper MS Topp LM Serrano S Gonzalez WC Chang A Naranjo C Wright L Popplewell A Raubitschek SJ Forman MC Jensen, Blood 2003 101 4 1637 44 10.1182/blood-2002-07-1989 12393484
21. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. TP Gade W Hassen E Santos G Gunset A Saudemont MC Gong R Brentjens XS Zhong M Stephan J Stefanski C Lyddane JR Osborne IM Buchanan SJ Hall WD Heston I Riviere SM Larson JA Koutcher M Sadelain, Cancer Res 2005 65 19 9080 8 10.1158/0008-5472.CAN-05-0436 16204083
22. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. RJ Brentjens E Santos Y Nikhamin R Yeh M Matsushita K La Perle A Quintas-Cardama SM Larson M Sadelain, Clin Cancer Res 2007 13 18 Pt 1 5426 35 10.1158/1078-0432.CCR-07-0674 17855649
23. Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors. R Meier M Piert G Piontek M Rudelius RA Oostendorp R Senekowitsch-Schmidtke TD Henning WS Wels C Uherek EJ Rummeny HE Daldrup-Link, Nucl Med Biol 2008 35 5 579 88 10.1016/j.nucmedbio.2008.02.006 18589302
24. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. HE Daldrup-Link R Meier M Rudelius G Piontek M Piert S Metz M Settles C Uherek W Wels J Schlegel EJ Rummeny, Eur Radiol 2005 15 1 4 13 10.1007/s00330-004-2526-7 15616814
25. Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo. A Biglari TD Southgate LJ Fairbairn DE Gilham, Gene Ther 2006 13 7 602 10 10.1038/sj.gt.3302706 16397508
26. Sheep red blood cells armed with anti-CD20 single-chain variable fragments (scFvs) fused to a glycosylphosphatidylinositol (GPI) anchor: a strategy to target CD20-positive tumor cells. N Hamdy AS Goustin JP Desaulniers M Li CS Chow A Al-Katib, J Immunol Methods 2005 297 1-2 109 24 10.1016/j.jim.2004.12.003 15777935
27. A system for the propagation of adenoviral vectors with genetically modified receptor specificities. JT Douglas CR Miller M Kim I Dmitriev G Mikheeva V Krasnykh DT Curiel, Nat Biotechnol 1999 17 5 470 5 10.1038/8647 10331807
28. Construction of tumor-specific cells expressing a membrane-anchored single-chain Fv of anti-ErbB-2 antibody. M Suzuki M Shinkai H Honda M Kamihira S Iijima T Kobayashi, Biochim Biophys Acta 2001 1525 1-2 191 6 11342269
29. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. RM Dwyer SM Potter-Beirne KA Harrington AJ Lowery E Hennessy JM Murphy FP Barry T O'Brien MJ Kerin, Clin Cancer Res 2007 13 17 5020 7 10.1158/1078-0432.CCR-07-0731 17785552
30. Approaches to utilize mesenchymal progenitor cells as cellular vehicles. L Pereboeva S Komarova G Mikheeva V Krasnykh DT Curiel, Stem Cells 2003 21 4 389 404 10.1634/stemcells.21-4-389 12832693
31. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. I Dmitriev V Krasnykh CR Miller M Wang E Kashentseva G Mikheeva N Belousova DT Curiel, J Virol 1998 72 12 9706 13 9811704
32. Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro. SP Zielske SL Gerson, Mol Ther 2002 5 4 381 7 10.1006/mthe.2002.0571 11945064
33. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. DB Kohn G Bauer CR Rice JC Rothschild DA Carbonaro P Valdez Q Hao C Zhou I Bahner K Kearns K Brody S Fox E Haden K Wilson C Salata C Dolan C Wetter E Aguilar-Cordova J Church, Blood 1999 94 1 368 71 10381536
34. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. R Schier A McCall GP Adams KW Marshall H Merritt M Yim RS Crawford LM Weiner C Marks JD Marks, J Mol Biol 1996 263 4 551 67 10.1006/jmbi.1996.0598 8918938
35. A mouse model for adenovirus gene delivery. T Tallone S Malin A Samuelsson J Wilbertz M Miyahara K Okamoto L Poellinger L Philipson S Pettersson, Proc Natl Acad Sci USA 2001 98 14 7910 5 10.1073/pnas.141223398 11438737
36. Selective induction of tumor-associated antigens in murine pulmonary vasculature using double-targeted adenoviral vectors. M Everts SA Kim-Park MA Preuss MJ Passineau JN Glasgow AV Pereboev PJ Mahasreshti WE Grizzle PN Reynolds DT Curiel, Gene Ther 2005 12 13 1042 8 10.1038/sj.gt.3302491 15789059
37. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. S Worgall G Wolff E Falck-Pedersen RG Crystal, Hum Gene Ther 1997 8 1 37 44 10.1089/hum.1997.8.1-37 8989993
38. Adenovirus serotype 5 hexon mediates liver gene transfer. SN Waddington JH McVey D Bhella AL Parker K Barker H Atoda R Pink SM Buckley JA Greig L Denby J Custers T Morita IM Francischetti RQ Monteiro DH Barouch N van Rooijen C Napoli MJ Havenga SA Nicklin AH Baker, Cell 2008 132 3 397 409 10.1016/j.cell.2008.01.016 18267072
39. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. J Gao JE Dennis RF Muzic M Lundberg AI Caplan, Cells Tissues Organs 2001 169 1 12 20 10.1159/000047856 11340257
40. Cell vehicle targeting strategies. JC Roth DT Curiel L Pereboeva, Gene Ther 2008 15 10 716 29 10.1038/gt.2008.38 18369326
41. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. AH Klopp EL Spaeth JL Dembinski WA Woodward A Munshi RE Meyn JD Cox M Andreeff FC Marini, Cancer Res 2007 67 24 11687 95 10.1158/0008-5472.CAN-07-1406 18089798
42. Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors. H Sato N Kuwashima T Sakaida M Hatano JE Dusak WK Fellows-Mayle GD Papworth SC Watkins A Gambotto IF Pollack H Okada, Cancer Gene Ther 2005 12 9 757 68 10.1038/sj.cgt.7700827 15832173
43. Early homing of adult mesenchymal stem cells in normal and infarcted isolated beating hearts. C Penna S Raimondo G Ronchi R Rastaldo D Mancardi S Cappello G Losano S Geuna P Pagliaro, J Cell Mol Med 2008 12 2 507 21 10.1111/j.1582-4934.2007.00121.x 18419594
44. In vivo analysis of a genetically modified adenoviral vector targeted to human CD40 using a novel transient transgenic model. M Izumi Y Kawakami JN Glasgow N Belousova M Everts S Kim-Park S Yamamoto M Wang LP Le PN Reynolds DT Curiel, J Gene Med 2005 7 12 1517 25 10.1002/jgm.806 16170831
45. Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. L Elzaouk K Moelling J Pavlovic, Exp Dermatol 2006 15 11 865 74 10.1111/j.1600-0625.2006.00479.x 17002683
46. Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. C Ren S Kumar D Chanda L Kallman J Chen JD Mountz S Ponnazhagan, Gene Ther 2008 15 21 1446 53 10.1038/gt.2008.101 18596829
47. Perspective: fundamental and clinical concepts on stem cell homing and engraftment: a journey to niches and beyond. PJ Quesenberry G Colvin M Abedi, Exp Hematol 2005 33 1 9 19 10.1016/j.exphem.2004.10.012 15661393
48. Autologous and Allogeneic Marrow Stromal Cells Are Safe and Effective for the Treatment of Acute Kidney Injury. F Togel A Cohen P Zhang Y Yang Z Hu C Westenfelder, Stem Cells Dev 2009 18 3 475 85 10.1089/scd.2008.0092 18564903
49. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. UM Fischer MT Harting F Jimenez WO Monzon-Posadas H Xue SI Savitz GA Laine CS Cox Jr, Stem Cells Dev 2009 18 5 683 92 10.1089/scd.2008.0253 19099374
50. Intravenous mesenchymal stem cell therapy for traumatic brain injury. MT Harting F Jimenez H Xue UM Fischer J Baumgartner PK Dash CS Cox, J Neurosurg 2009 110 6 1189 97 10.3171/2008.9.JNS08158 19301973
51. Transplanted bone marrow cells preferentially home to the vessels of in situ generated murine tumors rather than of normal organs. A Dwenger F Rosenthal M Machein C Waller A Spyridonidis, Stem Cells 2004 22 1 86 92 10.1634/stemcells.22-1-86 14688394
52. A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. H Jin A Aiyer J Su P Borgstrom D Stupack M Friedlander J Varner, J Clin Invest 2006 116 3 652 62 10.1172/JCI24751 16498499
53. Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. L Kucerova M Matuskova A Pastorakova S Tyciakova J Jakubikova R Bohovic V Altanerova C Altaner, J Gene Med 2008 10 10 1071 82 10.1002/jgm.1239 18671316
54. Mesenchymal stem cell administration at coronary artery reperfusion in the rat by two delivery routes: a quantitative assessment. SL Hale W Dai JS Dow RA Kloner, Life Sci 2008 83 13-14 511 5 10.1016/j.lfs.2008.07.020 18755200
55. Radiation Increases Invasion of Gene-modified Mesenchymal Stem Cells into Tumors. SP Zielske DL Livant TS Lawrence, Int J Radiat Oncol Biol Phys 2009 75 3 843 53 18849123